Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants
Latest Information Update: 29 Aug 2024
At a glance
- Drugs SP 0230 (Primary) ; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A C Y W-135 conjugate; PF 5212366
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 01 Aug 2024 Status changed from active, no longer recruiting to discontinued, due to Sponsor decision. Termination decision not related to any safety concern.
- 01 Feb 2024 According to a Sanofi media release, first participant has been treated.
- 01 Feb 2024 According to a Sanofi media release, results from this study were shared at the Vaccines event.